// App-Quantinova.ai

2589 : A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).

Researchers

Presenter

  • Michael J. Pishvaian

Principal Investigators

  • Hongkun Wang

  • Brandon George Smaglo

  • Jennifer Gao

  • Laura Macke

  • Erica Redmond

  • Eva Camilla Andersson Permaul

  • Supti Sen

  • Damian L. McCarthy

  • Bhaskar Kallakury

  • Stephen V. Liu

  • Aiwu Ruth He

  • Jimmy J. Hwang

  • Sandra M. Swain

  • John Marshall

  • Paula Raffin Pohlmann

Medical Centers

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

  • National Cancer Institute at the National Institutes of Health, Rockville, MD

  • Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC

  • NSABP/NRG Oncology, and The Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Retinoblastoma

Biomarkers

  • Proliferation marker protein Ki-67

  • Cyclin-dependent kinase 4

Drug/Treatment

  • Adrucil injection

  • Palbociclib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01522989

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved